MedPath

BIOKAD, AO

🇷🇺Russia
Ownership
-
Employees
-
Market Cap
-
Website

A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients

Phase 3
Completed
Conditions
Human Epithelial Receptor (HER)-2 Positive Breast Cancer
Interventions
First Posted Date
2013-01-09
Last Posted Date
2018-11-29
Lead Sponsor
Biocad
Target Recruit Count
225
Registration Number
NCT01764022
Locations
🇧🇾

Brest Region Clinical Oncology Dispensary, Brest, Belarus

🇧🇾

Gomel Region Clinical Oncology Dispensary, Gomel, Belarus

🇧🇾

Grodno Regional Hospital, Grodno, Belarus

and more 33 locations

A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer

Phase 3
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2013-01-09
Last Posted Date
2024-01-11
Lead Sponsor
Biocad
Target Recruit Count
353
Registration Number
NCT01763645
Locations
🇧🇾

Brest Regional Clinical Dispensary, Brest, Belarus

🇧🇾

Gomel Regional Clinical Oncology Dispensary, Gomel, Belarus

🇧🇾

Grodno Regional Clinical Hospital, Grodno, Belarus

and more 41 locations

Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
First Posted Date
2013-01-02
Last Posted Date
2017-03-27
Lead Sponsor
Biocad
Target Recruit Count
181
Registration Number
NCT01759030
Locations
🇧🇾

Gomel Regional Clinical Hospital, Gomel, Belarus

🇧🇾

City Clinical Hospital №1, Minsk, Belarus

🇧🇾

City Clinical Hospital №9, Minsk, Belarus

and more 37 locations

Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C

Phase 2
Completed
Conditions
Hepatitis
Hepatitis C
Interventions
First Posted Date
2012-12-04
Last Posted Date
2015-08-18
Lead Sponsor
Biocad
Target Recruit Count
150
Registration Number
NCT01740089
Locations
🇷🇺

Moscow State University of Medicine and Dentistry, Moscow, Russian Federation

Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma

Phase 3
Completed
Conditions
Nodal Marginal Zone Lymphoma
Splenic Marginal Zone Lymphoma
Follicular Non-Hodgkin's Lymphoma
First Posted Date
2012-10-05
Last Posted Date
2017-11-06
Lead Sponsor
Biocad
Target Recruit Count
174
Registration Number
NCT01701232
Locations
🇨🇴

Instituto Nacional de Cancerología, Bogotá, Colombia

🇨🇴

Fundación Reina Isabel, Cali, Colombia

🇨🇴

Hospital Pablo Tobon Uribe, Medellín, Colombia

and more 59 locations

Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer

Phase 2
Completed
Conditions
Chemotherapy-induced Neutropenia
First Posted Date
2012-04-02
Last Posted Date
2016-12-05
Lead Sponsor
Biocad
Target Recruit Count
60
Registration Number
NCT01569087
Locations
🇷🇺

Arkhangelsk District Clinical Oncology Dispensary, Arkhangelsk, Russian Federation

🇷🇺

Perm Region Oncology Dispensary, Perm, Russian Federation

🇷🇺

N.N.Petrov Oncology Research Center, St.Petersburg, Russian Federation

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath